Cure8 research brief
Standardized intestinal ultrasound scoring could help non-invasively monitor Crohn’s disease activity and reduce reliance on colonoscopy for some assessments. A high-sensitivity IUS score may be useful to rule out endoscopic activity during follow-up.
Clinicians who follow patients with Crohn’s disease, researchers studying non-invasive monitoring tools, and adult patients interested in non-endoscopic monitoring options.
This paper reports a cross-sectional observational study comparing the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) measured by intestinal ultrasound (IUS) with endoscopic disease activity (SES-CD) in 40 patients with ileal, colonic, or ileocolonic Crohn’s disease.
IBUS-SAS showed a moderate correlation with SES-CD and fecal calprotectin, and an AUC of 0.75 for detecting endoscopic activity; at a cut-off of 24 the score had very high sensitivity and a high negative predictive value.
The article presents segment-level analyses (160 bowel segments) and notes better diagnostic performance in transverse and left colon segments than in the terminal ileum and ascending colon. The authors suggest IBUS-SAS may be useful as a non-invasive rule-out and monitoring tool, but the full text is behind publisher access for figures and some details.
Overall this appears to be a single-center observational diagnostic accuracy study with a modest sample size; it supports use of a standardized IUS score for monitoring but does not provide prospective outcome or treatment-change data.
This is a diagnostic accuracy study with 40 patients and segment-level analyses; while promising, findings need replication in larger, multicenter cohorts and in prospective monitoring or treat-to-target trials. Some full-text content (figures/data) requires subscription access.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
